申请人:Boehringer Ingelheim GmbH
公开号:US04093734A1
公开(公告)日:1978-06-06
Compounds of the formula ##STR1## wherein (A) WHEN THE AMINO-SUBSTITUENT IS IN THE P-POSITION WITH RESPECT TO THE CARBONYL GROUP, R.sub.1 is chlorine in the o-position with respect to the carbonyl group, R.sub.2 is hydrogen, and R.sub.3 is ethylamino, cyclopentylamino, cyclohexylamino, cycloheptylamino, N-methyl-cyclohexylamino, benzylamino or 1-ethyl-pyrrolidyl-(2)-aminomethyl, or (b) when the amino-substituent is in the o--, m-- or p-position with respect to the carbonyl group, R.sub.1 is hydrogen, chlorine or bromine, R.sub.2 is trifluoromethyl, nitro or, when R.sub.4 is 1-(alkyl of 1 to 3 carbon atoms)-pyrrolidyl or 1-(alkyl of 1 to 3 carbon atoms)-piperidyl, also fluorine, chlorine, bromine or methyl, R.sub.3 is (alkyl of 1 to 5 carbon atoms)-amino, (cycloalkyl of 3 to 7 carbon atoms)-amino, benzylamino, quinuclidinyl-amino or --NH--(CH.sub.2).sub.n --R.sub.4 where R.sub.4 is pyridyl, 1-(alkyl of 1 to 3 carbon atoms)-pyrrolidyl, 1-(alkyl of 1 to 3 carbon atoms)-piperidyl or, when n is 2 or 3, also imidazolonyl, pyrrolidino, piperidino or morpholino, and n is 0, 1, 2 or 3, And non-toxic, pharmacologically acceptable acid addition salts thereof; the compounds as well as their salts are useful as anxiolytics, anticonvulsives, antiemetics and antiulcerogenics.
式为##STR1##的化合物,其中(a)当氨基取代物位于与羰基相对的p-位置时,R.sub.1是与羰基相对的o-位置的氯,R.sub.2是氢,R.sub.3是乙基氨基,环戊基氨基,环己基氨基,环庚基氨基,N-甲基环己基氨基,苄氨基或1-乙基吡咯啉基(2)-氨基甲基;或(b)当氨基取代物位于与羰基相对的o-、m-或p-位置时,R.sub.1是氢,氯或溴,R.sub.2是三氟甲基,硝基或者当R.sub.4是1-(含1至3个碳原子的烷基)-吡咯啉基或1-(含1至3个碳原子的烷基)-哌啶基时,也可以是氟、氯、溴或甲基,R.sub.3是(含1至5个碳原子的烷基)-氨基,(含3至7个碳原子的环烷基)-氨基,苄氨基,喹啉基氨基或--NH--(CH.sub.2).sub.n --R.sub.4,其中R.sub.4是吡啶基,1-(含1至3个碳原子的烷基)-吡咯啉基,1-(含1至3个碳原子的烷基)-哌啶基或者当n为2或3时,也可以是咪唑基,吡咯啉基,哌啶基或吗啉基,n为0、1、2或3。以及其非毒性、药理学上可接受的酸盐;这些化合物及其盐可用作抗焦虑药、抗抽搐药、抗恶心药和抗溃疡药。